OPB 31121
Alternative Names: OPB-31121Latest Information Update: 05 Nov 2023
Price :
$50 *
At a glance
- Originator Otsuka Pharmaceutical
- Class Antineoplastics
- Mechanism of Action STAT3 transcription factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer; Leukaemia; Liver cancer; Multiple myeloma; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Solid tumours
Most Recent Events
- 30 Sep 2015 Discontinued - Phase-I for Cancers in South Korea, USA, Japan & Hong Kong (PO)
- 30 Sep 2015 Discontinued - Phase-I/II for liver cancer in Japan (PO)
- 21 Sep 2015 No recent reports on development identified - Phase-I for Cancer in USA (PO)